Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Xolair under the microscope: how well does it work for nasal polyps in real life?

NCT ID NCT05626257

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how safe and effective Xolair is for adults with chronic rhinosinusitis and nasal polyps when used in routine care. 135 patients who were already prescribed Xolair were followed to track side effects and changes in symptoms. The goal was to see how the drug performs outside of strict clinical trial settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xolair (omalizumab)
What this could lead to
If successful, this could confirm that Xolair is a safe and effective option for managing nasal polyps in everyday medical practice.
What could go wrong
This is a post-marketing surveillance study, not a controlled trial, so results may be less definitive. It also does not test a new treatment, just monitors existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

135 people

The number who actually took part.

Started

Jan 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

this study will involve patients who received at least one dose of Xolair® for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) according to the current label information in Korea.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS) 3. Patients prescribed with Xolair® as per the locally approved label information. 4. Patients who provide written informed consent to participate in the study Exclusion Criteria: 1. Patients who do not provide consent to participate in the study 2. Patients participating in other clinical trial 3. Contraindications listed in the locally approved label information of Xolair® * Hypersensitivity to the active ingredient or any other ingredient of Xolair® * Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis with nasal polyps are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinosinusitis with nasal polyps

Contacts and locations

Locations

  • Novartis Investigative Site

    Anyang-si, Gyeonggi-do, 14068, South Korea

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    Incheon, Korea, 405 760, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 03312, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 07061, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 08308, South Korea

  • Novartis Investigative Site

    Seoul, Yangcheon gu, 07985, South Korea

  • Novartis Investigative Site

    Daegu, 705 718, South Korea

  • Novartis Investigative Site

    Gyeonggi-do, 14353, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 06351, South Korea

  • Novartis Investigative Site

    Seoul, 07804, South Korea

  • Novartis Investigative Site

    Seoul, 2447, South Korea

  • Novartis Investigative Site

    Suwon, 16247, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.